AI R&D Manager

Aqemia.Com; Paris; Sur place; EUR 120 000 - 160 000; Plein temps

Avantages offerts par ce poste

Flexible work arrangement

Offices in Paris and London

Strong funding

Résumé du poste

AQEMIA in Paris and London seeks a Manager of Molecular Generation to lead a multidisciplinary team of 6+ scientists. You will guide structure-based AI generative models, apply physics-based methods, and advance novel, synthesizable molecules.

The role blends strategic leadership with hands-on ML, chemistry, and software engineering, requiring a PhD or MSc, 2+ years of team leadership, and a track record in Generative AI. Flexible hybrid work with strong funding and startup culture.

Qualifications

• Minimum 2+ years leading a machine learning team, computational R&D in drug discovery or related field.
• Proven expertise in Generative AI techniques.
• Experience translating scientific research into scalable product roadmaps and hands-on ML deployments.

Responsabilités

• Define and execute roadmaps for structure-based AI generative models.
• Hire, manage and mentor a 6+ person team of AI researchers and computational chemists.
• Integrate physics-based calculations into the generative ML workflow to improve molecular realism.
• Communicate progress and risks clearly to stakeholders.
• Collaborate with downstream teams to ensure smooth handoffs of models.

Connaissances

Leadership

Strategic planning

Communication

Problem solving

Formation

Master's or PhD in ML or related field

Outils

Python

MLOps

Cloud computing

Computational chemistry tools

Description du poste

About AQEMIA

AQEMIA is a drug invention company dedicated to creating entirely new medicines to address major unmet medical needs. At the core of our mission is QEMI, our proprietary molecule-invention platform, which uniquely combines cutting-edge science with advanced technology. Powered by physics-based modeling, statistical mechanics, and generative AI, QEMI allows our teams to design novel drug candidates from first principles.

What makes AQEMIA different is our commitment to true innovation: our research is dedicated to the invention of new molecular entities, not the refinement of existing ones. We focus on inventing never-before-seen molecules, without relying on experimental data, and advancing them into a growing pipeline of proprietary programs and strategic partnerships with leading pharmaceutical companies.

Our most advanced preclinical programs are currently in vivo optimization, targeting diseases still waiting for effective treatments, offering our teams the opportunity to work on science that can make a real difference in people’s lives.

For more information, visit AQEMIA.com, our WTTJ Page, and our LinkedIn.

About our Team

AQEMIA brings together a diverse, multidisciplinary team of 80+ professionals based in Paris and London. Our scientists and engineers, including chemists, physicists, machine learning experts, and software engineers, work side by side to push the boundaries of early-stage drug discovery.

This close collaboration across disciplines is central to our approach, enabling us to tackle complex scientific challenges from first principles and translate cutting-edge ideas into novel therapeutic candidates. At AQEMIA, team members are encouraged to contribute their expertise, learn from one another, and play an active role in shaping the future of drug invention.

About our Platform Department

The Platform team (about 20 people) brings together multidisciplinary teams working on the scientific core of Aqemia’s drug discovery engine. Its mission is to build scalable and reproducible workflows enabling multiple drug discovery programs to run in parallel with minimal manual intervention.

The team combines expertise across Artificial Intelligence and Machine Learning (both research and applications), data science, statistical physics and molecular simulations, computational chemistry (CADD), and other scientific disciplines. Together, they develop predictive models, physics-based simulations, and robust scientific pipelines that power AQEMIA\'s discovery platform.

At the center of this ecosystem is the Rocket Launcher process: an industrialized workflow continuously launching, testing, and improving drug discovery projects through iterative scientific feedback loops.

The role

As Manager of Molecular Generation Team, you will lead the multidisciplinary team responsible for developing our methods to design novel, highly potent and synthesizable molecules. You will be responsible for leveraging physics-based methods and state-of-the-art Machine Learning techniques to guide molecular design, focusing specifically on 3D structural constraints and target interactions.

• Strategic & Technical Leadership:
• Define and execute the roadmap for developing structure-based AI generative models.
• Establish clear, measurable KPIs for synthesis success and novelty of generated molecules.
• Drive the integration of physics-based calculations into the Generative Machine Learning workflow to enhance the chemical realism and relevance of generated molecules.
• People & Team Management:
• Hire, manage and mentor a highly skilled team of 6+ scientists, encompassing AI Research Scientists and Computational Chemists.
• Own the recruitment process for key technical hires, ensuring the team maintains world-class expertise at the intersection of chemistry, physics and AI.
• Foster a culture of high performance, psychological safety and continuous learning, providing technical guidance and growth opportunities for individual contributors.
• Collaboration & Delivery:
• Ensure seamless handoff of molecular generation algorithm to downstream teams.
• Enable integration of physics and AI-based predictors in the molecular generation workflow.
• Communicate complex scientific progress and strategic risks clearly.
• Master degree or PhD in Machine Learning, Computational Chemistry, Statistical Mechanics, Physics, Computer Science or a related field.
• Minimum of 2+ years of experience leading a machine learning team, computational R&D team in Drug Discovery or a closely related field.
• Proven expertise in Generative AI techniques.
• Proficiency in Python, experience with MLOps and cloud computing environments.
• Ability to translate fundamental scientific research into a clear, scalable product roadmap that aligns with commercial goals.
• Exceptional ability to communicate complex concepts to both specialized scientists and non-technical stakeholders.
• Proven ability to manage risk, handle scientific failure inherent in R&D, and lead an autonomous team in a fast-paced startup environment.
• Pragmatic and Impact-Driven - Focused on delivering solutions that work in real-world applications, balancing scientific rigor with practical usability.
• Eagerness to Learn - A strong curiosity for scientific advancements and a willingness to continuously expand your expertise.
• Love for High Scientific Challenges - Enthusiasm for tackling complex problems at the frontier of AI and drug discovery.
• Team-Oriented - A collaborative spirit, thriving in an interdisciplinary environment.
• Humility - Open to feedback and different perspectives, always striving for improvement.

Why Join Us?

At AQEMIA, we work for a mission: joining us means having your own impact on changing the way drugs are discovered, and helping to shape the direction of our fast-growing company and team.

Expanding Drug Discovery Pipeline: Focused on critical therapeutic areas like Oncology, CNS, Immuno-inflammation... with in vivo proof of concept/patent stage programs. Collaborations with top Pharma, including a $140M Sanofi deal.

World-Class Interdisciplinary Team: work alongside exceptional talent at the intersection of technology and life sciences. Our teams combine deep expertise in AI, physics-based modeling, biology, and medicinal chemistry to push the boundaries of innovation.

DeepTech Recognition: AQEMIA is proud to be part of the French Tech 120 and France 2030, highlighting our role as a key player in Europe’s DeepTech ecosystem.

Prime Location with Flexibility: Our offices are located in the heart of Paris and London (King’s Cross), with flexible work arrangements including up to two remote days per week.

Strong Financial Backing: 100M raised from leading European and International investors